Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer

Xin Zhang; Zheng Xu; Xiangpeng Dai; Xiaoling Zhang; Xueju Wang

doi:10.3389/fimmu.2023.1104860

Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer

Front Immunol. 2023 Jan 25:14:1104860. doi: 10.3389/fimmu.2023.1104860. eCollection 2023.

Authors

Xin Zhang¹, Zheng Xu¹, Xiangpeng Dai^{2

3}, Xiaoling Zhang^{2

3}, Xueju Wang¹

Affiliations

¹ Department of Pathology, China-Japan Union Hospital, Jilin University, Changchun, Jilin, China.
² Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, First Hospital of Jilin University, Changchun, China.
³ National-Local Joint Engineering Laboratory of Animal Models for Human Disease, First Hospital of Jilin University, Changchun, China.

Abstract

The mutation of the crucial genes such as tumor suppressors or oncogenes plays an important role in the initiation and development of tumors. The non-synonymous mutations in the tumor cell genome will produce non-autologous proteins (neoantigen) to activate the immune system by activating CD4+ and CD8+ T cells. Neoantigen-based peptide vaccines have exhibited exciting therapeutic effects in treating various cancers alone or in combination with other therapeutic strategies. Furthermore, antigen-loaded DC vaccines are more powerful in inducing stronger immune responses than vaccines generated by antigens and adjuvants. Therefore, neoantigen-based dendritic cell (DC) vaccines could achieve promising effects in combating some malignant tumors. In this review, we summarized and discussed the recent research progresses of the neoantigen, neoantigen-based vaccines, and DC-based vaccine in pancreatic cancers (PCs). The combination of the neoantigen and DC-based vaccine in PC was also highlighted. Therefore, our work will provide more detailed evidence and novel opinions to promote the development of a personalized neoantigen-based DC vaccine for PC.

Keywords: cancer vaccines; dendritic cell; immunotherapy; mutation burden; neoantigen; pancreatic cancer.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antigens, Neoplasm*
CD8-Positive T-Lymphocytes
Dendritic Cells
Humans
Pancreatic Neoplasms* / genetics
Pancreatic Neoplasms* / metabolism
Pancreatic Neoplasms* / therapy

Substances

Antigens, Neoplasm

Grants and funding

This work is supported by the Young Scientists Fund of the National Natural Science Foundation of China (No: 81700198), the Science and Technology Development Project of Jilin Province (No: 20190701064GH).